Download PDF
Semin Thromb Hemost 2005; 31(1): 66-72
DOI: 10.1055/s-2005-863807
Copyright © 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Multilaboratory Testing in Thrombophilia through the United Kingdom National External Quality Assessment Scheme (Blood Coagulation) Quality Assurance Program

Ian Jennings1 , 2 , Steven Kitchen2 , Timothy A. L. Woods2 , F. Eric Preston2
  • 1Deputy Scheme Manager, United Kingdom NEQAS (Blood Coagulation), Sheffield, United Kingdom
  • 2United Kingdom NEQAS (Blood Coagulation), Sheffield, United Kingdom
Further Information

Publication History

Publication Date:
11 February 2005 (online)

    Permissions and Reprints

ABSTRACT

We describe here results from the United Kingdom National External Quality Assessment Scheme (UK NEQAS) Thrombophilia Screening Program, in which an average of 21% of 280 centers reported an incorrect diagnosis for a series of plasma samples. Three case studies are described, showing causes of error in individual laboratories, related to the source of reference plasma or reagents. Methodological bias is also described. For protein C (PC) assays 18% of centers reported PC deficiency in a patient homozygous for factor V Leiden. Studies in the NEQAS laboratory confirmed the effect of activated protein C resistance (APCR) on clot-based PC activity assays. Differences in results obtained for PS-deficient subjects with different protein S (PS) activity kits are reported; several subjects would be misdiagnosed as normal with one kit if the manufacturer's reported reference range was adopted instead of a locally determined reference range. Antithrombin (AT) assays were shown to vary in their sensitivity to different molecular defects in the antithrombin gene; 77% of centers employing human thrombin-based activity assays reported a normal AT level in a patient with antithrombin Cambridge II. Sensitivity of the APC resistance test in the absence of factor V-deficient plasma was shown to be improved through normalization of results, and errors in the genetic diagnosis of factor V Leiden and the P20210A prothrombin gene mutation are described. Errors in the diagnosis of thrombophilic defects can therefore be identified through participation in EQA programs, and following dissemination of information, improvements in diagnosis can be demonstrated.

KEYWORDS

Quality assurance testing - antithrombin - protein C - protein S - activated protein C resistance - factor V Leiden - prothrombin gene mutation

REFERENCES

  • 1 Faioni E M, Mannucci P M. Diagnostic testing for familial thrombophilia. In: Rowan RM, van Assendelft OW, Preston FE Advanced Laboratory Methods in Haematology London; Arnold 2002
    Google Scholar
  • 2 Egeberg O. On the natural blood coagulation system. Investigations of inhibitor factors based on antithrombin deficient blood.  Thromb Diath Haemorrh. 1965;  14 473-489
    PubMedGoogle Scholar
  • 3 Haemostasis and Thrombosis Task Force, British Committee for Standards in Haematology. Investigation and management of heritable thrombophilia.  Br J Haematol. 2001;  114 512-528
    CrossrefPubMedGoogle Scholar
  • 4 Tripodi A, Mannucci P M. Laboratory investigation of thrombophilia.  Clin Chem. 2001;  47 1597-1606
    PubMedGoogle Scholar
  • 5 Torrano-Masetti L, Rizzatti E G, Oliveira L CO, Inácio R A, Santos M A, Franco R F. Psychologic impact of thrombophilia screening in asymptomatic relatives of carriers of prothrombotic mutations. J Thromb Haemost 2003 1(suppl 1): (abst OC322)
    Google Scholar
  • 6 Greaves M, Cohen H, Machin S J, Mackie I. Guidelines on the investigation and management of the antiphospholipid syndrome.  Br J Haematol. 2000;  109 704-715
    CrossrefPubMedGoogle Scholar
  • 7 Kitchen S, Walker I D, Woods TA L, Preston F E. on behalf of the Steering Committee of the UK NEQAS in Blood Coagulation . Thromboplastin related differences in the determination of International Normalised Ratio: A cause for concern?.  Thromb Haemost. 1994;  72 426-429
    PubMedGoogle Scholar
  • 8 Jennings I, Kitchen S, Cooper P, Makris M, Preston F E. Sensitivity of functional protein S assays to protein S deficiency: a comparative study of three commercial kits.  J Thromb Haemost. 2003;  1 1112-1114
    CrossrefPubMedGoogle Scholar
  • 9 Preston F E, Kitchen S, Jennings I, Woods T A. A UK National External Quality Assessment scheme (UK NEQAS) for molecular genetic testing for the diagnosis of familial thrombophilia.  Thromb Haemost. 1999;  82 1556-1557
    PubMedGoogle Scholar
  • 10 Cunningham M T, Praestgaard J, Styer P E et al.. A method for proficiency testing of small peer groups in the College of American Pathologists Coagulation Surveys.  Arch Pathol Lab Med. 1999;  123 199-205
    PubMedGoogle Scholar
  • 11 Meijer P, Kluft C, Haverkate F, De Maat M P. The long-term within- and between-laboratory variability for assay of antithrombin, and proteins C and S: results derived from the external quality assessment program for thrombophilia screening of the ECAT Foundation.  J Thromb Haemost. 2003;  1 748-753
    CrossrefPubMedGoogle Scholar
  • 12 Faioni E M, Franchi F, Asti D, Sacchi E, Bernardi F, Mannucci P M. Resistance to activated protein C in nine thrombophilic families: interference in a protein S functional assay.  Thromb Haemost. 1993;  70 1067-1071
    PubMedGoogle Scholar
  • 13 Cooper P C, Hampton K K, Makris M, Abuzenadah A, Paul B, Preston F E. Further evidence that activated protein C resistance can be misdiagnosed as inherited functional protein S deficiency.  Br J Haematol. 1994;  88 201-203
    PubMedGoogle Scholar
  • 14 Ireland H, Bayston T, Thompson E et al.. Apparent heterozygous type II protein C deficiency caused by the factor V 506 Arg to Gln mutation.  Thromb Haemost. 1995;  73 731-732
    PubMedGoogle Scholar
  • 15 Simioni P, de Ronde H, Prandoni P, Saladini M, Bertina R M, Girolami A. Ischemic stroke in young patients with activated protein C resistance: a report of three cases belonging to three different kindreds.  Stroke. 1995;  26 885-890
    PubMedGoogle Scholar
  • 16 Jennings I, Kitchen S, Cooper P C, Rimmer J E, Woods T A, Preston F E. Further evidence that activated protein C resistance affects protein C coagulant activity assays.  Thromb Haemost. 2000;  83 171-172
    PubMedGoogle Scholar
  • 17 De Stefano V, Finazzi G, Mannucci P M. Inherited thrombophilia: pathogenesis, clinical syndromes and management.  Blood. 1996;  87 3531-3544
    PubMedGoogle Scholar
  • 18 Lane D A, Mannucci P M, Bauer K A et al.. Inherited thrombophilia, Part 1.  Thromb Haemost. 1996;  76 651-662
    PubMedGoogle Scholar
  • 19 Faioni E M. Protein S activity. In: Jespersen J, Bertina RM, Haverkate F Laboratory Techniques in Thrombosis: A Manual Amsterdam; Kluwer Academic 1999
    Google Scholar
  • 20 Demers C, Henderson P, Blajchman M A et al.. An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition.  Thromb Haemost. 1993;  69 231-235
    PubMedGoogle Scholar
  • 21 De Visser M C, Rosendaal F R, Bertina R M. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis.  Blood. 1999;  93 1271-1276
    PubMedGoogle Scholar
  • 22 De Ronde H, Bertina M. Laboratory diagnosis of APC resistance: a critical evaluation of the test and development of diagnostic criteria.  Thromb Haemost. 1994;  72 880-886
    PubMedGoogle Scholar
  • 23 Tripodi A, Chantarangkul V, Negri B, Mannucci P M. Standardisation of the APC resistance test. Effects of normalisation of results by means of pooled normal plasma.  Thromb Haemost. 1998;  79 564-566
    PubMedGoogle Scholar
  • 24 Jennings I, Kitchen S, Woods T A, Preston F E. Normalization does not improve between-laboratory agreement but may improve specificity of some assays for activated protein C resistance.  Blood Coagul Fibrinolysis. 1999;  10 451-453
    PubMedGoogle Scholar
  • 25 Brandt G, Gruppo R, Glueck C J et al.. Sensitivity, specificity and predictive value of modified assays for activated protein C resistance in children.  Thromb Haemost. 1998;  79 567-570
    PubMedGoogle Scholar
  • 26 Lutz C T, Foster P A, Noll W W et al.. Multicenter evaluation of PCR methods for the detection of factor V Leiden (R506Q) genotypes.  Clin Chem. 1998;  44 1356-1358
    PubMedGoogle Scholar
  • 27 Tripodi A, Peyvandi F, Chantarangkul V, Menegatti M, Mannucci P M. Relatively poor performance of clinical laboratories for DNA analyses in the detection of two thrombophilic mutations-a cause for concern.  Thromb Haemost. 2002;  88 690-691
    PubMedGoogle Scholar
  • 28 Jennings I, Kitchen S, Woods T AL, Preston F E, Greaves M. Clinically important inaccuracies in testing for the lupus anticoagulant: an analysis of results from three surveys of the UK NEQAS for Blood Coagulation.  Thromb Haemost. 1997;  77 934-937
    PubMedGoogle Scholar
  • 29 Jennings I, Greaves M, Mackie I J, Kitchen S, Woods T A, Preston F E. UK National External Quality Assessment Scheme for Blood Coagulation. Lupus anticoagulant testing: improvements in performance in a UK NEQAS proficiency testing exercise after dissemination of national guidelines on laboratory methods.  Br J Haematol. 2002;  119 364-369
    CrossrefPubMedGoogle Scholar
  • 30 Jennings I, Kitchen S, Smith J, Woods T A, Preston F E. Between-centre agreement in homocysteine assays: experience from the UK NEQAS proficiency testing scheme.  Thromb Haemost. 2002;  87 921-922
    PubMedGoogle Scholar

Ian JenningsPh.D. 

UK NEQAS for Blood Coagulation, Rutledge Mews, 3 Southbourne Road

Sheffield S10 2QN, United Kingdom

Email: ian@coageqa.org.uk

      >